“…These agents also have a role in patients who have had arterial cerebral vascular accidents, 21,22 in patients who are in hemodynamic shock from pulmonary emboli, and in patients with venous thrombosis at other sites. [23][24][25][26][27][28]29,30 As for PNH, there have been a number of papers in the literature, [10][11][12][13][14][15][17][18][19]31,32 most of them on isolated cases. Here we report our experience with thrombolytic therapy in a highly selected group of nine patients with PNH, all of whom had severe thrombotic complications, which were regarded as potentially fatal if not treated, or which were progressing despite anticoagulation: in this respect, tissue plasminogen activator (tPA) can be regarded as a second-line treatment for patients with PNH complicated by venous thrombosis.…”